SusanC.ModesittMDFACOG, FACS

Obstetrics & Gynecology • Atlanta, GA

Gynecologic Oncology

Division director Gynecologic Oncology Professor of Gynecology and Obstetrics Emory University School of Medicine

Join to view full profile

Dr. Modesitt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Modesitt's full profile

Already have an account?

Office
Emory Clinic at 1365 Clifton Rd
1365 Clifton Rd NE
Atlanta, GA 30322
Phone+1 434-778-2471
Is this information wrong?

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1999 - 2002
University of North Carolina HospitalsResidency, Obstetrics and Gynecology, 1995 - 1999
University of Virginia School of MedicineClass of 1995
Emory University BS, Biology, Magna cum laude, 1987 - 1991

Certifications & Licensure

GA State Medical License 2022 - 2025
VA State Medical License 2006 - 2024
KY State Medical License 2002 - 2007
NC State Medical License 1996 - 2006
TX State Medical License 2000 - 2002
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2022
America's Top Doctors for Cancer Castle Connolly, 2011-2022
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20
Completed
Phase 2
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer Start of enrollment: 2005 Oct 01
Completed
Phase 2
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer Start of enrollment: 2008 Mar 10
Completed
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 2
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Start of enrollment: 2010 Jun 07
Completed
Neoadjuvant Therapy for Ovarian Cancer Start of enrollment: 2010 May 17
Completed
Phase 2
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Active, not recruiting
Phase 3
Study of Menstrual Irregularities and Endometrial Pathology in Women Undergoing Bariatric Surgery Start of enrollment: 2011 Jan 01
Completed
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of di...
Cynthia A Thomson, Tracy E Crane, Austin Miller, Michael A Gold, Matthew Powell, Kristin Bixel, Linda Van Le, Paul DiSilvestro, Elena Ratner, Shashikant Lele, Saketh G...> ;Gynecologic Oncology. 2023 Mar 1
Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer - Navigating maintenance therapy for homologous recombinant proficient ...
Whitney N Goldsberry, Barbara S Norquist, Rodney P Rocconi, Susan C Modesitt, Renata R Urban> ;Gynecologic Oncology Reports. 2022 Dec 1
Ridiculously good writing: How to write like a pro and publish like a boss.
Susan C Modesitt, Laura J Havrilesky, Rebecca A Previs, J Alejandro Rauh-Hain, J Michael Straughn, Jamie N Bakkum-Gamez, Katherine C Fuh, David E Cohn> ;Gynecologic Oncology Reports. 2022 Aug 1
Optimizing post-operative opiate prescribing following gynecologic surgery.
Katherine M Croft, Bethany M Sarosiek, Elisa Trowbridge, C Page Muthusubramanian, Traci Hedrick, Susan C Modesitt> ;Gynecologic Oncology Reports. 2022 Aug 1
1 citations
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.
Phuong L Mai, Austin Miller, Amanda Black, Roni T Falk, John F Boggess, Katherine Tucker, Ashley R Stuckey, Gustavo C Rodriguez, Cheung Wong, Thomas T Amatruda, Kelly ...> ;American Journal of Obstetrics and Gynecology. 2022 Jul 1
7 citations
Beneficial effects of exercise on chemotherapy-induced peripheral neuropathy and sleep disturbance: A review of literature and proposed mechanisms.
L Brett Whalen, W Zachary Wright, Priyanka Kundur, Siddhartha Angadi, Susan C Modesitt> ;Gynecologic Oncology Reports. 2022 Feb 1
Editorial.
Susan C Modesitt> ;Gynecologic Oncology Reports. 2022 Feb 1
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Lari Wenzel, Helen Q. Huang, David Cella, Chelsea O. McKinney, Michael A. Zevon, Jason A. Lachance, Joan L. Walker, Ritu Salani, Susan C. Modesitt, Robert T. Morris, W...> ;Gynecologic Oncology. 2021 Sep 20
Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients.
Amanda M. Lulu, Kara L. Cummings, Erin D. Jeffery, Paisley T. Myers, Dennis J. Underwood, Rachel M Lacy, Kimberly A. Chianese-Bullock, Craig L. Slingluff, Susan C. Mod...> ;Cancer Immunology Research. 2021 Aug 19
1 citations
MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
Brett Kurpiel, Martha Thomas, Mansoor Mubeen, Kari L. Ring, Susan C. Modesitt, Christopher A. Moskaluk, Anne M. Mills> ;International Journal of Gynecological Pathology. 2021 Feb 11
5 citations
Development and Impact of an Institutional Enhanced Recovery Program on Opioid Use, Length of Stay, and Hospital Costs Within an Academic Medical Center: A Cohort Anal...
Robert H. Thiele, Bethany M. Sarosiek, Susan C. Modesitt, Timothy L. McMurry, Mohamed Tiouririne, Linda W. Martin, Randal S. Blank, Ashley M. Shilling, James A. Browne...> ;Anesthesia and Analgesia. 2021 Feb 1
1 citations
"Moving Away From Cancer" Prospective Exercise Trial for Female Rural Cancer Survivors: How Can We Step It Up?
Susan C. Modesitt, Natalie Z.M. Eichner, J. Kim Penberthy, Bethany J. Horton, Martha E Stewart, Rachel M Lacy, Arthur Weltman> ;JCO Oncology Practice. 2021 Jan 1
6 citations
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian,...
Linda R. Duska, Carolyn N. Krasner, David M. O'Malley, John L. Hays, Susan C. Modesitt, Cara Mathews, Kathleen N. Moore, Premal H. Thaker, Anthony B. Miller, Christoph...> ;Gynecologic Oncology. 2021 Mar 1
Perioperative Impact of Widespread Implementation of an Enhanced Recovery Protocol on Short-term Outcomes in Cancer Patients.
Allison N. Martin, Taryn E. Hassinger, Kevin T. Lynch, Linda W. Martin, Susan C. Modesitt, Robert H. Thiele, Traci L. Hedrick> ;Journal of Gastrointestinal Surgery. 2021 May 1
40 citations
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
Claire F. Friedman, Alexandra Snyder Charen, Qin Zhou, Michael A. Carducci, Alexandre Buckley de Meritens, Bradley R. Corr, Siqing Fu, Travis J. Hollmann, Alexia Iason...> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
4 citations
Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
Madison R. Klavans, Sarah H. Erickson, Susan C. Modesitt> ;Gynecologic Oncology Reports. 2020 Aug 25
5 citations
Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion
Ji Son, Laura M. Chambers, Caitlin Carr, Chad M. Michener, Meng Yao, Anna Beavis, Ting Tai Yen, Rebecca L. Stone, Stephanie L. Wethington, Amanda N. Fader, Wesley C. B...> ;International Journal of Gynecological Cancer. 2020 Aug 7
2 citations
Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
Christine Garcia, Mackenzie W. Sullivan, Heather Lothamer, Kara Harrison, Lindsay Chatfield, Martha H. Thomas, Susan C. Modesitt> ;The Journal of Obstetrics and Gynaecology Research. 2020 Sep 1
Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic.
Anne Knisely, Martha E. Stewart, Christine Garcia, Martha H. Thomas, Susan C. Modesitt, Kari L. Ring> ;Gynecologic Oncology Reports. 2020 May 22
4 citations
Optimal age for genetic cancer predisposition testing in hereditary SMARCA4 Ovarian Cancer Families: How young is too young?
Sarah Podwika, Taylor M. Jenkins, Joyti K Khokhar, Sarah H. Erickson, Susan C. Modesitt> ;Gynecologic Oncology Reports. 2020 Apr 7
12 citations
Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
Anna Beavis, Ting Tai Yen, Rebecca L. Stone, Stephanie L. Wethington, Caitlin Carr, Ji Son, Laura M. Chambers, Chad M. Michener, Stephanie Ricci, Wesley C. Burkett, De...> ;Gynecologic Oncology. 2020 Jan 14
21 citations
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Shannon N. Westin, Michael W. Sill, Robert L. Coleman, Steven E. Waggoner, Kathleen N. Moore, Cara Mathews, Lainie P. Martin, Susan C. Modesitt, Sanghoon Lee, Zhenlin ...> ;Gynecologic Oncology. 2019 Dec 1
1 citations
Practical Cancer Genetics and Genomics in Women's Health.
Susan C. Modesitt, Holly J. Pederson, Royce T. Adkins> ;Clinical Obstetrics and Gynecology. 2019 Dec 1
1 citations
When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors.
Mackenzie W. Sullivan, Susan C. Modesitt> ;Southern Medical Journal. 2019 Dec 1
3 citations
Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GO...
Gustavo C. Rodriguez, James Kauderer, Jessica Hunn, Larry G. Thaete, William G. Watkin, Samantha J. Russell, Michael Yozwiak, Jack Basil, Jean A. Hurteau, Shashikant L...> ;Cancer Prevention Research. 2019 Jun 1
Join now to see all

Journal Articles

Enhanced Recovery Program for Minimally Invasive and Vaginal Urogynecologic Surgery
Dana L Redick, Traci L Hedrick, Susan C Modesitt, Robert H Thiele, Elisa Rodriguez Trowbridge, Kathie L Hullfish, International Urogynecology Journal

Press Mentions

Surgeons Can Reduce Impact of Ovarian Cancer by Promoting Opportunistic SalpingectomiesMarch 14th, 2023
Hair Straighteners: What’s the Impact on Uterine Cancer Risk?December 23rd, 2022
Facing Cancer in the Midst of Motherhood and Her Medical Career, Dr. Kelleher Gains a Deep Gratitude for Her UVA Colleagues and Empathy for Her PatientsAugust 22nd, 2019
Join now to see all